Skip to content
10-K

Annual Report

Keros Therapeutics, Inc. KROS

0001664710-26-000018

← back to feed
Filed
Mar 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 19.72M sh
Shares Diluted FY 2025 · Dec 31, 2025 37.86M sh
Shares Diluted FY 2025 · Dec 31, 2024 37.44M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $375M
Stock Repurchased FY 2025 · Oct 20, 2025 $194.4M
Stock Repurchased FY 2025 · Oct 15, 2025 $180.6M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Capex FY 2025 · Dec 31, 2025 $1.55M
Capex FY 2025 · Dec 31, 2024 $1.93M
Operating Cash Flow FY 2025 · Dec 31, 2025 $107.51M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$160.87M
Cash And Equivalents FY 2025 · Dec 31, 2025 $287.42M
Cash And Equivalents FY 2025 · Dec 31, 2024 $559.93M
Stockholders Equity FY 2025 · Dec 31, 2025 $303.13M
Stockholders Equity FY 2025 · Dec 31, 2024 $571.55M
Stockholders Equity FY 2025 · Dec 31, 2023 $332.21M
Current Liabilities FY 2025 · Dec 31, 2025 $20.41M
Current Liabilities FY 2025 · Dec 31, 2024 $27.45M
Total Liabilities FY 2025 · Dec 31, 2025 $34.89M
Total Liabilities FY 2025 · Dec 31, 2024 $44.33M
Current Assets FY 2025 · Dec 31, 2025 $315.43M
Current Assets FY 2025 · Dec 31, 2024 $588.89M
Total Assets FY 2025 · Dec 31, 2025 $338.02M
Total Assets FY 2025 · Dec 31, 2024 $615.89M
Eps Diluted FY 2025 · Dec 31, 2025 $2.30
Eps Diluted FY 2025 · Dec 31, 2024 −$5.00
Eps Basic FY 2025 · Dec 31, 2025 $2.34
Eps Basic FY 2025 · Dec 31, 2024 −$5.00
Sga Expense FY 2025 · Dec 31, 2025 $46.85M
Sga Expense FY 2025 · Dec 31, 2024 $40.75M
Rd Expense FY 2025 · Dec 31, 2025 $129.64M
Rd Expense FY 2025 · Dec 31, 2024 $173.63M
Net Income FY 2025 · Dec 31, 2025 $87.01M
Net Income FY 2025 · Dec 31, 2024 −$187.35M
Operating Income FY 2025 · Dec 31, 2025 $67.57M
Operating Income FY 2025 · Dec 31, 2024 −$210.83M
Revenue FY 2025 · Dec 31, 2025 $244.06M
Revenue FY 2025 · Dec 31, 2024 $3.55M